By Counterforce Health Team in Rezlidhia (olutasidenib) —

How to Get Rezlidhia (olutasidenib) Covered by Humana in Virginia: Forms, Timelines, and Appeal Scripts

Answer Box: Getting Started Today

Rezlidhia (olutasidenib) requires prior authorization from Humana and likely a formulary exception since it's not on most 2024-2025 formularies. Your fastest path: Have your oncologist submit Humana's PA form with IDH1 mutation test results, prior therapy documentation, and a medical necessity letter within 72 hours for standard decisions. If denied, you have 65 days to appeal internally, then 120 days to request external review through Virginia's State Corporation Commission. Start today: Call Humana at 800-555-2546 to confirm your plan's formulary status and obtain the current PA form.

Table of Contents

Coverage Requirements at a Glance

Requirement Details Documentation Needed Source
Prior Authorization Required for all Humana plans PA form + supporting docs Humana Policy
Formulary Status Likely non-formulary (exception needed) Exception request form Humana Drug Lists
Diagnosis Relapsed/refractory AML with IDH1 mutation IDH1 test results, pathology report FDA Label
Prescriber Board-certified oncologist/hematologist Medical license verification Humana Policy
Step Therapy May require ivosidenib trial first Prior therapy records or contraindication Humana Formulary
Appeals Deadline 65 days from denial notice Denial letter, medical records Medicare Guidelines

Step-by-Step: Fastest Path to Approval

1. Verify Coverage Details (Day 1)

Who: Patient or caregiver
Action: Call Humana member services at 800-555-2546
Ask for: Current formulary status, PA requirements, your specific plan's pharmacy benefit structure
Timeline: 15-30 minutes

2. Gather Required Documentation (Days 1-3)

Who: Patient with clinic support
Documents needed:

  • IDH1 mutation test results (FDA-approved assay)
  • Complete AML diagnosis and staging records
  • Documentation of all prior therapies and outcomes
  • Current performance status and lab values
  • Insurance card and member ID

3. Oncologist Submits Prior Authorization (Days 3-5)

Who: Prescribing oncologist or clinic staff
Submit: Humana PA form with medical necessity letter
Methods: Online provider portal, fax, or mail
Timeline: 72 hours for standard review, 24 hours if expedited

4. Request Formulary Exception (If Non-Formulary)

Who: Prescriber
Form: Medicare Prescription Drug Coverage Determination Form
Justification: Document why formulary alternatives are unsuitable
Timeline: 72 hours for decision

5. Monitor and Follow Up

Track: Via Humana member portal or phone
Prepare: Appeal documentation if denial expected
Next steps: Internal appeal within 65 days if denied

Understanding Your Denial Letter

When Rezlidhia is denied, carefully review the denial letter to identify the specific reason. Common denial codes include:

  • Non-formulary: Drug not covered under your plan
  • Prior authorization required: Missing PA submission
  • Step therapy: Must try alternative first (typically ivosidenib)
  • Medical necessity: Insufficient clinical justification
  • Prescriber specialty: Non-oncologist prescriber
Tip: Look for the specific policy number referenced in your denial. This helps your oncologist address the exact coverage criteria in appeals.

First-Level Internal Appeal

Required Components

Your internal appeal must include:

  • Original denial letter
  • Updated medical necessity letter from oncologist
  • Complete IDH1 mutation test report
  • Prior therapy documentation showing failures or contraindications
  • Recent clinic notes supporting current medical necessity
  • Patient impact statement (optional but helpful)

Submission Process

Deadline: 65 days from denial notice date
Methods:

  • Online: Humana member portal
  • Phone: 800-555-2546
  • Mail: Address provided in denial letter
  • Fax: Number specified in your plan materials

Timeline: 30 days for standard appeals, 72 hours for expedited

Peer-to-Peer Review Strategy

Request a peer-to-peer review when the denial involves medical necessity. This allows your oncologist to speak directly with Humana's medical director.

Preparation Checklist

  • Patient's complete treatment history
  • IDH1 mutation specifics and clinical significance
  • NCCN guideline references supporting Rezlidhia use
  • Contraindications or failures with alternative IDH1 inhibitors
  • Expected clinical outcomes and monitoring plan

Key Talking Points

  • FDA approval for exact indication (relapsed/refractory AML with IDH1 mutation)
  • Specific IDH1 mutation subtype and clinical relevance
  • Prior therapy failures with documented outcomes
  • Why alternatives like ivosidenib are inappropriate for this patient
From our advocates: In peer-to-peer calls, oncologists who present a clear timeline of prior treatments and specific mutation details often see better success rates. Having lab values and performance status readily available helps demonstrate immediate medical need.

External Review Through Virginia SCC

If Humana upholds the denial after internal appeals, Virginia residents can request external review through the State Corporation Commission Bureau of Insurance.

Eligibility Requirements

  • Must complete Humana's internal appeal process first
  • Denial must be based on medical necessity or experimental treatment determination
  • Must file within 120 days of final internal denial

Filing Process

Form: Form 216-A External Review Request
Submit to: SCC Bureau of Insurance, P.O. Box 1157, Richmond, VA 23218
Phone: 877-310-6560
Cost: Free

Timeline

  • Standard review: 45 days
  • Expedited review: 72 hours (requires physician certification of urgent need)

At Counterforce Health, we help patients navigate complex prior authorization and appeals processes by analyzing denial letters, identifying specific policy requirements, and drafting evidence-based appeals that align with each payer's criteria. Our platform streamlines the documentation process and improves approval rates for specialty medications like Rezlidhia.**

Medical Necessity Letter Template

Your oncologist's letter should include these essential elements:

Patient Information Section

[Patient Name], DOB: [Date], Member ID: [Number]
Diagnosis: Relapsed/refractory acute myeloid leukemia with IDH1 mutation
IDH1 Mutation: [Specific mutation, e.g., R132H] confirmed by [FDA-approved test]

Treatment History

Previous therapies:
1. [Induction therapy] - [dates] - [outcome/reason for discontinuation]
2. [Salvage therapy] - [dates] - [outcome/reason for discontinuation]
Current performance status: [ECOG score]

Clinical Rationale

Rezlidhia (olutasidenib) is FDA-approved specifically for relapsed/refractory AML 
with susceptible IDH1 mutations. This patient's [specific mutation] makes them 
an ideal candidate for targeted IDH1 inhibition. Alternative therapies including 
[list alternatives] are not appropriate because [specific medical reasons].

Safety Monitoring Plan

Monitoring protocol includes:
- Weekly CBC with differential for first month
- Liver function tests every 2 weeks
- Differentiation syndrome surveillance per FDA guidelines
- Follow-up visits every 2 weeks initially

Common Denial Reasons & Solutions

Denial Reason Solution Required Documentation
Non-formulary File formulary exception Comparative effectiveness data, contraindications to formulary alternatives
Step therapy Document ivosidenib failure/contraindication Prior therapy records, adverse event documentation
Medical necessity Enhanced clinical justification NCCN guidelines, mutation-specific efficacy data
Prescriber specialty Confirm oncology certification Board certification, hospital privileges
Insufficient documentation Complete submission IDH1 test, pathology, prior therapy records

Cost Assistance Options

Manufacturer Support

Rigel Pharmaceuticals Patient Support: Visit Rezlidhia.com for copay assistance and patient access programs.

Foundation Grants

  • Leukemia & Lymphoma Society Patient Aid Program
  • CancerCare Copay Assistance Foundation
  • Patient Access Network Foundation

Medicare Extra Help

Low-income Virginia residents may qualify for Medicare's Extra Help program, reducing copays to $4.50-$11.20 per prescription.

Frequently Asked Questions

How long does Humana prior authorization take in Virginia? Standard PA decisions are made within 72 hours. Expedited requests (when health is at risk) are decided within 24 hours.

What if Rezlidhia is non-formulary on my Humana plan? You can request a formulary exception. Your oncologist must document why formulary alternatives would be less effective or cause adverse effects.

Can I request an expedited appeal if my condition is urgent? Yes. If your oncologist certifies that delays could jeopardize your health, Humana must decide expedited appeals within 72 hours, and Virginia external reviews within 72 hours.

Does step therapy apply if I received treatment outside Virginia? Prior therapies received anywhere in the U.S. count toward step therapy requirements. Ensure your oncologist includes complete treatment records from all providers.

What happens if Virginia external review upholds the denial? The decision is final and binding. However, you retain rights to pursue legal action separately if you believe the denial violated insurance law.

How much will Rezlidhia cost with Humana coverage? As a specialty medication, Rezlidhia typically falls under Tier 4 or 5, requiring 25-33% coinsurance plus any applicable deductible. Exact costs depend on your specific plan.

For patients navigating the complex world of specialty drug approvals, Counterforce Health provides comprehensive support by analyzing payer policies, identifying denial reasons, and crafting targeted appeals that speak directly to each insurer's specific requirements.

When to Escalate to Virginia Regulators

If you believe Humana improperly denied coverage or failed to follow proper procedures, contact:

Virginia State Corporation Commission
Bureau of Insurance
Phone: 877-310-6560
Website: SCC.Virginia.gov

File a complaint if:

  • Appeals deadlines weren't met
  • Required forms weren't provided
  • Medical necessity was improperly evaluated
  • Procedural requirements were ignored

Sources & Further Reading

Disclaimer: This information is for educational purposes only and does not constitute medical or legal advice. Coverage decisions depend on individual plan terms and medical circumstances. Always consult with your healthcare provider and insurance plan for personalized guidance. For official Virginia insurance regulations and appeal procedures, contact the State Corporation Commission Bureau of Insurance at 877-310-6560.

Powered by Counterforce Health—AI that turns drug denials into evidence-based appeals patients and clinicians can submit today.